TY - JOUR
T1 - Early successes in an open access, provincially funded hepatitis C treatment program in Prince Edward Island
AU - Francheville, Jordan W.
AU - Rankin, Robin
AU - Beck, Jeremy
AU - Hoare, Connie
AU - Materniak, Stefanie
AU - German, Greg
AU - Barrett, Lisa
AU - Bunimov-Wall, Natalie
AU - Smyth, Daniel
N1 - Publisher Copyright:
© 2017, Fundacion Clinica Medica Sur. All rights reserved.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Introduction. The availability of curative hepatitis C therapies has created an opportunity to improve treatment delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the first year of program implementation. Material and methods. Using a community-based prospective observational study design, all chronic hepatitis C referrals received from April 2015 to April 2016 were recorded in a database. Primary analysis assessed the time from referral to assessment/treatment, as well as the number of referrals, assessments, and treatment initiations. Secondary objectives included: 1) treatment effectiveness using intention-to-treat analysis; and 2) patient treatment experience assessed using demographics, adverse events, and medication adherence. Results. During the study period 242 referrals were received, 123 patients were seen for intake assessments, and 93 initiated direct-acting antiviral therapy based on medical need. This is compared to 4 treatment initiations in the previous 2 years. The median time from assessment to treatment initiation was 3 weeks. Eighty-two of 84 (97.6%, 95% CI 91.7 - 99.7%) patients for whom outcome data were available achieved sustained virologic response at 12 weeks post-treatment; 1 was lost to follow-up and 1 died from an unrelated event. In the voluntary registry, 39.7% of patients reported missed treatment doses. Conclusion. In conclusion, results from the first 12 months of this multi-phase hepatitis C elimination strategy demonstrate improved access to treatment, and high rates of safe engagement and cure for patients living with chronic hepatitis C genotype 1 infections.
AB - Introduction. The availability of curative hepatitis C therapies has created an opportunity to improve treatment delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the first year of program implementation. Material and methods. Using a community-based prospective observational study design, all chronic hepatitis C referrals received from April 2015 to April 2016 were recorded in a database. Primary analysis assessed the time from referral to assessment/treatment, as well as the number of referrals, assessments, and treatment initiations. Secondary objectives included: 1) treatment effectiveness using intention-to-treat analysis; and 2) patient treatment experience assessed using demographics, adverse events, and medication adherence. Results. During the study period 242 referrals were received, 123 patients were seen for intake assessments, and 93 initiated direct-acting antiviral therapy based on medical need. This is compared to 4 treatment initiations in the previous 2 years. The median time from assessment to treatment initiation was 3 weeks. Eighty-two of 84 (97.6%, 95% CI 91.7 - 99.7%) patients for whom outcome data were available achieved sustained virologic response at 12 weeks post-treatment; 1 was lost to follow-up and 1 died from an unrelated event. In the voluntary registry, 39.7% of patients reported missed treatment doses. Conclusion. In conclusion, results from the first 12 months of this multi-phase hepatitis C elimination strategy demonstrate improved access to treatment, and high rates of safe engagement and cure for patients living with chronic hepatitis C genotype 1 infections.
UR - http://www.scopus.com/inward/record.url?scp=85027563597&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027563597&partnerID=8YFLogxK
U2 - 10.5604/01.3001.0010.2757
DO - 10.5604/01.3001.0010.2757
M3 - Article
C2 - 28809740
AN - SCOPUS:85027563597
SN - 1665-2681
VL - 16
SP - 749
EP - 758
JO - Annals of Hepatology
JF - Annals of Hepatology
IS - 5
ER -